Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Stock market today: Dow, S&P 500, Nasdaq cut losses as oil prices drop

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq cut losses as oil prices drop US stocks cut losses on Thursday as oil prices went negative in afternoon trading on hopes of a deescalation of the conflict in the Middle East…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The war will end faster than people think

    60% confidence

  • Rotation is the lifeblood of a bull market

    60% confidence

  • The oil shock could put downward pressure on growth

    60% confidence

  • Zero employment growth equilibrium is a balance, but not a comfortable balance

    60% confidence

  • Inflationary pressures are showing greater persistence

    60% confidence

  • $200 billion for the war in Iran is a small price to pay

    60% confidence

  • Inflation had now been over target for five years

    60% confidence

  • The next Fed policy move will likely be a rate hike in the first half of 2027

    60% confidence

  • Israel is helping the US open the Strait of Hormuz

    60% confidence

  • The macroeconomic environment is challenging and may not be as favorable going forward

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq cut losses as oil prices drop — Source | Via News | Via News